Welcome to Snoretox Ltd.
Inventing a drug to resolve BOAS (Brachycephalic Obstructive Airways Syndrome) along with human muscle weakness conditions.
This convention is the leading deal-making convention for veterinary pharmaceutical companies in the USA, attended by veterinary pharmaceutical companies along with the new products seeking deals. The highly credentialed judges selected us unanimously from the 41 applicants. This award was made after a presentation about our muscle-targeted neuromuscular stimulant drug in dogs suffering from BOAS Syndrome, where the drug is injected into the muscles in the floor of the mouth. We continue to attract a high level of interest, and new opportunities are opening up. This award has both supported this momentum and added value to our company.
Our timeline to success
2025
2024
2022
Snoretox was today singled out in the announcement $100 million for the Breakthrough Victoria – University Innovation Platform.
‘Snoretox is another example of a company commercialising RMIT-developed technology – a novel muscle toning toxin-based therapeutic for treating sleep apnea and snoring, as well as a range of other weak muscle conditions such as incontinence.’
2021
Snoretox wins a Medical Research Future Fund (MRFF) 2021 Frontier Health and Medical Research Initiative Grant, securing a $1 million grant.
The MRFF is a 20 Billion dollar fund set up by the Australian Federal Government to promote medical research and it’s translation to the clinic.
2020
2020
First Scientific Publication: Molecular Immunology. Volume 127. November 2020
In the laboratories of RMIT University, in Melbourne, Australia, we have invented and patented the world’s first effective and long-lasting drug for muscle weakness.
Our game-changing technology is based on molecules of tetanus toxin, modified to ensure they work around the tetanus vaccine.
Just as Botox uses tiny amounts of botulinum toxin to relax muscles, our prototype therapeutic uses minute amounts of tetanus toxin to achieve the opposite effect – muscle toning.
Snoretox dogs are happy dogs!
Novel modified tetanus toxin muscle toning biotherapeutics for:
- BOAS
- Sleep apnoea and snoring
- Muscle recovery
- Sphincter weakness (anal, oesophageal, bladder, pelvic floor)
- Neurological (Multiple Sclerosis, Motor Neuron Disease, Myopathy)
- Veterinary (sleep apnoea, “roaring” larynx disorders, sphincter incontinence, muscle weakness)
- Cosmetic muscle toning (eyelid issues such as ectropion and ptosis, facial and chin lifting, general muscle toning)
Our therapeutics are trademarked SnoretoxTM (for sleep apnoea) and TonetoxTM (for other applications).
